全文获取类型
收费全文 | 8878篇 |
免费 | 471篇 |
国内免费 | 43篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 192篇 |
妇产科学 | 114篇 |
基础医学 | 1208篇 |
口腔科学 | 283篇 |
临床医学 | 616篇 |
内科学 | 2078篇 |
皮肤病学 | 279篇 |
神经病学 | 984篇 |
特种医学 | 201篇 |
外科学 | 1040篇 |
综合类 | 38篇 |
现状与发展 | 1篇 |
预防医学 | 449篇 |
眼科学 | 289篇 |
药学 | 706篇 |
中国医学 | 16篇 |
肿瘤学 | 846篇 |
出版年
2023年 | 62篇 |
2022年 | 136篇 |
2021年 | 200篇 |
2020年 | 127篇 |
2019年 | 175篇 |
2018年 | 173篇 |
2017年 | 149篇 |
2016年 | 207篇 |
2015年 | 205篇 |
2014年 | 252篇 |
2013年 | 310篇 |
2012年 | 550篇 |
2011年 | 644篇 |
2010年 | 347篇 |
2009年 | 272篇 |
2008年 | 514篇 |
2007年 | 545篇 |
2006年 | 513篇 |
2005年 | 546篇 |
2004年 | 533篇 |
2003年 | 490篇 |
2002年 | 486篇 |
2001年 | 131篇 |
2000年 | 135篇 |
1999年 | 139篇 |
1998年 | 109篇 |
1997年 | 57篇 |
1996年 | 78篇 |
1995年 | 74篇 |
1994年 | 51篇 |
1993年 | 48篇 |
1992年 | 110篇 |
1991年 | 84篇 |
1990年 | 104篇 |
1989年 | 93篇 |
1988年 | 95篇 |
1987年 | 88篇 |
1986年 | 84篇 |
1985年 | 64篇 |
1984年 | 57篇 |
1983年 | 33篇 |
1982年 | 27篇 |
1981年 | 17篇 |
1980年 | 29篇 |
1979年 | 32篇 |
1978年 | 23篇 |
1975年 | 16篇 |
1974年 | 20篇 |
1968年 | 16篇 |
1967年 | 16篇 |
排序方式: 共有9392条查询结果,搜索用时 15 毫秒
81.
82.
Technology developed to allow recovery of cells without enzyme treatment, involving a dish grafted with a thermoreactive polymer gel of poly-N-isopropylacrylamide (PIPAAm), was found to significantly enhance gap junctional intercellular communication (GJIC) in normal human dermal fibroblasts (NHDF cells). NHDF cells were cultured for 4 days on PIPAAm-grafted dishes irradiated with various doses of electron beams, and GJIC was assayed by the scrape-loading dye transfer method. The area of dye transfer was greater in the PIPAAm-grafted dishes than in the control culture dishes, indicating that the PIPAAm-grafted dishes enhanced the GJIC of NHDF cells. Connexin-43 (Cx43) expression was analyzed because Cx43 is considered to be a main component of the gap junctional channel. PIPAAm-grafted dishes irradiated with 100, 250, or 500 kGy of electron beams showed significantly enhanced expression of Cx43-NP, Cx43-P1, and especially Cx43-P2. Enhanced expression of Cx43-P2, a functional transmembrane protein, may be related to the promotion of GJIC. These results suggest that the PIPAAm-grafted dish not only enables the enzyme-free recovery of a cell monolayer for use in the construction of a three-dimensional artificial tissue, but also significantly contributes to the enhancement of GJIC, which may partly promote tissue strength on the surface of the PIPAAm-grafted dish. 相似文献
83.
Unsu Jung Jason E Foley Andreas A Erdmann Yoko Toda Todd Borenstein Jacopo Mariotti Daniel H Fowler 《Biology of blood and marrow transplantation》2006,12(9):905-918
Rapamycin prevention of murine graft-versus-host disease (GVHD) is associated with a shift toward Th2- and Tc2-type cytokines. Recently, we found that use of rapamycin during ex vivo donor Th2 cell generation enhances the ability of adoptively transferred Th2 cells to prevent murine GVHD. In this study, using a method, without antigen-presenting cells, of T-cell expansion based on CD3,CD28 costimulation, we evaluated whether (1) rapamycin preferentially promotes the generation of Th2/Tc2 cells relative to Th1/Tc1 cells, (2) rapamycin-generated T-cell subsets induce cytokine skewing after allogeneic bone marrow transplantation (BMT), and (3) such in vivo cytokine skewing is sensitive to post-BMT rapamycin therapy. Contrary to our hypothesis, rapamycin did not preferentially promote Th2/Tc2 cell polarity, because rapamycin-generated Th1/Tc1 cells secreted type I cytokines (interleukin [IL]-2 and interferon-gamma) did not secrete type II cytokines (IL-4, IL-5, IL-10, or IL-13) and mediated fasL-based cytolysis. Rapamycin influenced T-cell differentiation, because each of the Th1, Th2, Tc1, and Tc2 subsets generated in rapamycin had increased expression of the central-memory T-cell marker, L-selectin (CD62L). Rapamycin-generated Th1/Tc1 and Th2/Tc2 cells were not anergic but instead had increased expansion after costimulation in vitro, increased expansion in vivo after BMT, and maintained full capacity to skew toward type I or II cytokines after BMT, respectively; further, rapamycin-generated Th1/Tc1 cells mediated increased lethal GVHD relative to control Th1/Tc1 cells. Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing. In conclusion, ex vivo and in vivo usage of rapamycin may be used to modulate the post-BMT balance of Th1/Tc1 and Th2/Tc2 cell subsets. 相似文献
84.
Ken-Ichi Maeda Hideyuki Nagasawa Atsuko Furukawa Hajime Hisaeda Yoichi Maekawa Tetsuya Manabe Eiji Kudo Robert A. Good Kunisuke Himeno 《European journal of immunology》1993,23(12):3151-3157
To examine the development of T cells within an allogeneic or xenogeneic environment, we engrafted the fetal thymus from AKR mice or F344 rats under the kidney capsule of SCID mice (mTG and rTG mice). T lymphopoiesis developed in SCID mice 2 months after transplantation, although the ratio of CD4/CD8 in both experimental groups was different from that of normal control. T cells in mTG mice did not show in vitro proliferation or cytotoxicity against either host-type C.B-17 (H-2d) or donor-type AKR (H-2k) cells, while they exerted potent activities against third-party BIO (H-2b) cells. In contrast, T cells in rTG mice exhibited proliferation against both host-type C.B-17 and donor-type F344 rat cells. Consistently, graft-vs.-host disease symptoms developed in these mice and histological examination showed impressive infiltration of lymphocytes into the skin or into the mucosal layers of the stomach. Activated state of T cells in rTG mice was also evidenced by the positive expression of interleukin-2 receptor. Taken together, fetal thymus appears to contain progenitor cells which are sufficient for in vivo reconstitution of T lymphopoiesis, but species-specific environment is important for the induction of tolerance. In mTG mice, Vβ6+ T cells reactive to donor Mlsa determinants and Vβ3+ T cells reactive to host Mlsc determinants were deleted, suggesting that tolerance was regulated mainly by clonal deletion. By contrast, Vβ11+ T cells reactive to Mlsf determinants were not deleted possibly due to the lack of their ligands. 相似文献
85.
86.
87.
Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia 总被引:3,自引:0,他引:3
Niihori T Aoki Y Ohashi H Kurosawa K Kondoh T Ishikiriyama S Kawame H Kamasaki H Yamanaka T Takada F Nishio K Sakurai M Tamai H Nagashima T Suzuki Y Kure S Fujii K Imaizumi M Matsubara Y 《Journal of human genetics》2005,50(4):192-202
Noonan syndrome (NS) is characterized by short stature, characteristic facial features, and heart defects. Recently, missense mutations of PTPN11, the gene encoding protein tyrosine phosphatase (PTP) SHP-2, were identified in patients with NS. Further, somatic mutations in PTPN11 were detected in childhood leukemia. Recent studies showed that the phosphatase activities of five mutations identified in NS and juvenile myelomonocytic leukemia (JMML) were increased. However, the functional properties of the other mutations remain unidentified. In this study, in order to clarify the differences between the mutations identified in NS and leukemia, we examined the phosphatase activity of 14 mutants of SHP-2. We identified nine mutations, including a novel F71I mutation, in 16 of 41 NS patients and two mutations, including a novel G503V mutation, in three of 29 patients with leukemia. Immune complex phosphatase assays of individual mutants transfected in COS7 cells showed that ten mutants identified in NS and four mutants in leukemia showed 1.4-fold to 12.7-fold increased activation compared with wild-type SHP-2. These results suggest that the pathogenesis of NS and leukemia is associated with enhanced phosphatase activity of mutant SHP-2. A comparison of the phosphatase activity in each mutant and a review of previously reported cases showed that high phosphatase activity observed in mutations at codons 61, 71, 72, and 76 was significantly associated with leukemogenesis. 相似文献
88.
Kiyoji Kimura Ryuzo Ohno Ichita Amaki Kenichi Hattori Yutaka Hirota Akira Hoshino Michito Ichimaru Munemoto Ito Ikuo Kimura Tadashi Maekawa Toru Masaoka Toru Nakamura Makoto Ogawa Masao Oguro Kazuo Ohta Shigeyuki Osamura Masanori Shimoyama Fumimaro Takaku Yoshiro Uzuka Kazumasa Yamada 《Medical oncology (Northwood, London, England)》1986,3(1):15-24
A phase I study ofN 4-behenoyl-1-β-d-arabinofuranosylcytosine (BHAC) was conducted in 66 patients, 41 with solid tumors and 25 with hematological malignancies. The patients received either a 2-h single intravenous (i.v.) drip infusion (Schedule 1) or consecutive daily 2-h i.v. infusions (Schedule 2). In Schedule 1 the daily dose was initiated with 1.5 mg kg?1 which was escalated up to 7 mg kg?1. Side-effects were mild, and included nausea, vomiting, epilation, and hot flushes. Because of the presence of the solvent vehicle, HCO-60 and in consideration of the mechanism of action of BHAC, the dose escalation was stopped at 7 mg kg?1. In Schedule 2, the daily dose was started with 1.5 mg kg?1 which was escalated up to 8 mg kg?1 and given for 2–16 days. Myelosuppression was found to be dose-limiting toxicity. The maximum tolerated dose (MTD) in patients with non-hematological solid tumors was assumed to be 5 mg kg?1 daily × 5 days. The plasma disappearance curve of BHAC looked biphasic, and when 4 mg kg?1 of BHAC were administered the half-lives of the initial phase (t 1/2α) and the second phase (t 1/2β) were calculated as 0.798 and 5.76 h respectively. In Schedule 2 complete remission was observed in 5 out of 21 patients with acute leukemia, one partial remission in Hodgkin’s disease, and one 1-B response (Karnofsky) in thyroid papillary adenocarcinoma. 相似文献
89.
Kenya Kusunose Yuichiro Okushi Yoshihiro Okayama Robert Zheng Miho Abe Michikazu Nakai Yoko Sumita Takayuki Ise Takeshi Tobiume Koji Yamaguchi Shusuke Yagi Daiju Fukuda Hirotsugu Yamada Takeshi Soeki Tetsuzo Wakatsuki Masataka Sata 《Nutrients》2021,13(2)
A broad range of chronic conditions, including heart failure (HF), have been associated with vitamin D deficiency. Existing clinical trials involving vitamin D supplementation in chronic HF patients have been inconclusive. We sought to evaluate the outcomes of patients with vitamin D supplementation, compared with a matched cohort using real-world big data of HF hospitalization. This study was based on the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). After exclusion criteria, we identified 93,692 patients who were first hospitalized with HF between April 2012 and March 2017 (mean age was 79 ± 12 years, and 52.2% were male). Propensity score (PS) was estimated with logistic regression model, with vitamin D supplementation as the dependent variable and clinically relevant covariates. On PS-matched analysis with 10,974 patients, patients with vitamin D supplementation had lower total in-hospital mortality (6.5 vs. 9.4%, odds ratio: 0.67, p < 0.001) and in-hospital mortality within 7 days and 30 days (0.9 vs. 2.5%, OR, 0.34, and 3.8 vs. 6.5%, OR: 0.56, both p < 0.001). In the sub-group analysis, mortalities in patients with age < 75, diabetes, dyslipidemia, atrial arrhythmia, cancer, renin-angiotensin system blocker, and β-blocker were not affected by vitamin D supplementation. Patients with vitamin D supplementation had a lower in-hospital mortality for HF than patients without vitamin D supplementation in the propensity matched cohort. The identification of specific clinical characteristics in patients benefitting from vitamin D may be useful for determining targets of future randomized control trials. 相似文献
90.